Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) a clinical stage one of the best Biotech Stocks developing next generation targeted drugs for the treatment of cancer announced an update on the efficacy and safety of RX-3117 in an underway Phase IIa clinical study in metastatic pancreatic cancer at the ASCO 2017 held in California.
Ely Benaim, M.D., the Chief Medical Officer for Rexahn, reported that the progression free survival data in metastatic pancreatic cancer subjects treated with RX-3117 is encouraging with 20% of subjects showcasing progression free survival of over 5.6 months. A majority of the subjects enrolled in the study have already failed three or more prior cancer treatments. Current alternatives for these patients are limited to best supportive or palliative care; there are no medications permitted for metastatic pancreatic cancer subjects that have failed 2 or more prior treatments.
Peter D. Suzdak, Ph.D., the CEO of Rexahn, reported that the company’s development plan for RX-3117 in pancreatic cancer is to develop RX-3117 as mono treatment for subjects with metastatic disease who have not responded to two or more prior treatments, and also, in parallel, to advance RX-3117 together with Abraxane® for people with metastatic pancreatic cancer who obtained no previous chemotherapy therapy.
Since there are no medications approved for people who have failed 2 or more treatments, there may be an accelerated official pathway for approval for this population, assuming the company continue to record efficacy with RX-3117. Additionally, in the first quarter, Rexahn intends to initiate a Phase 2a clinical study of RX-3117 together with Abraxane® in patients newly diagnosed with metastatic pancreatic cancer. They expect the initial report from this trial to be available in 2018.
The updated efficacy report for RX-3117 from an underway Phase IIa clinical study in metastatic pancreatic cancer were released on January 20, 2017. On Thursday, the Biotech Stocks was trading 4% down in early trading hours.